Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Mehr anzeigen
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid...
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.95 | -6.27062706271 | 15.15 | 15.59 | 13.82 | 696472 | 14.42623317 | CS |
| 4 | -10.66 | -42.8801287208 | 24.86 | 25.88 | 13.82 | 822580 | 17.84668464 | CS |
| 12 | -20.62 | -59.2188397473 | 34.82 | 36.54 | 13.82 | 585301 | 22.02289988 | CS |
| 26 | -9.66 | -40.486169321 | 23.86 | 41.3083 | 13.82 | 439798 | 26.67394172 | CS |
| 52 | -6.81 | -32.4131366016 | 21.01 | 41.3083 | 13.82 | 384735 | 25.27083613 | CS |
| 156 | -22.88 | -61.7044228695 | 37.08 | 41.3083 | 13.36 | 296477 | 23.89829353 | CS |
| 260 | -3.08 | -17.8240740741 | 17.28 | 41.3083 | 11.95 | 313161 | 22.78363328 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
